Andon Health Co., Ltd (SHE: 002432), a leading healthcare company based in China, has announced that it has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its novel triplex test kit, capable of detecting COVID-19, influenza A virus, and influenza B virus. The product is designed for over-the-counter (OTC) use in households, facilitating qualitative detection and differentiation of these viruses from front nasal swab samples within four days of the onset of respiratory infectious disease symptoms in individuals aged two and above.
Given the similar clinical presentations of respiratory viral infections and the need for distinct treatment plans and medications, the US FDA has established an emergency use authorization channel to address the seasonal surge in respiratory infectious diseases. Andon Health’s test kit is poised to play a crucial role in enabling rapid and accurate diagnosis, thereby aiding in the implementation of appropriate treatment strategies.
In a similar development, Guangzhou Wondfo Biotech Co., Ltd (SHE: 300482), another Chinese firm, was granted EUA by the US FDA for a comparable product just days prior, highlighting the proactive response of Chinese healthcare companies to global health challenges.- Flcube.com
